EU publishes much-awaited revision to its guidance on borderline products
This article was originally published in SRA
The European Commission has updated its guidance on borderline products, offering further clarity on cases where it is not clear from the outset whether a given product is a medical device, an in vitro diagnostic or a medicinal product1,2.
You may also be interested in...
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.
Drug companies will be able to “play around” with the new EU Clinical Trials Information System in a secure testing environment before it goes live in approximately 15 months.